Sales of a new portable CT scanner helped Analogic post recordrevenues and earnings for its fourth quarter and fiscal 1996 (end-July).Analogic also saw gains in other areas of its medical technologybusiness, according to officials with the Peabody, MA,
Sales of a new portable CT scanner helped Analogic post recordrevenues and earnings for its fourth quarter and fiscal 1996 (end-July).Analogic also saw gains in other areas of its medical technologybusiness, according to officials with the Peabody, MA, vendor.
For the year, Analogic posted revenue of $230.5 million, up10% compared with sales of $208.8 million the year before. Netincome for 1996 stood at $13.1 million, up from $12.7 millionin fiscal 1995.
Despite the year-over-year gains, it was in the fourth quarterthat Analogic saw real growth. Revenues for the most recent periodwere a record $70.4 million, up 25% compared with $56.3 millionin the same period last year. Net income grew to $5.9 million,compared with $4.2 million in the fourth quarter of 1995.
The revenue growth is due to higher sales in Analogic's medicaltechnology business, according to senior vice president and treasurerJohn Tarello. In particular, Analogic experienced strong fourth-quartersales of a portable CT scanner that went into production in January,Tarello said.
Analogic has licensed the system to Philips Medical Systems,which sells the unit in two versions as Tomoscan/M and Tomoscan/EG(SCAN 2/15/95). Philips debuted the scanner to the Asian marketat the International Congress of Radiology meeting in Beijinglast June (SCAN 7/17/96).
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.